| BIAL - PORTELA & CA, S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120077973 | Sulphonylated Diphenylethylenediamines, Method for Their Preparation and Use in Transfer Hydrogenation Catalysis - A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X | 03-29-2012 |
| 20110301204 | ADMINISTRATION REGIME FOR NITROCATECHOLS - The present invention relates to novel dosage regimens for compounds of formula I: where the substituents are as defined in the specification. | 12-08-2011 |
| 20110237803 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 09-29-2011 |
| 20110166360 | Catalytic Process for Asymmetric Hydrogenation - A process for preparing the S or R enantiomer of a compound of formula A, | 07-07-2011 |
| 20110112303 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 05-12-2011 |
| 20110112301 | CRYSTAL FORMS OF 5-[3-(2,5-DICHLORO-4, 6-DIMETHYL-1-OXY-PYRIDINE-3-YL)[1,2,4] OXADIAZOL-5-YL]-3-NITROBENZENE-1,2-DIOL - This invention relates to novel polymorphs of (HO) | 05-12-2011 |
| 20100298580 | Process for the Preparation of 2H-Chromene-3-Carbamate Derivatives - Compounds of formula I, V, VI and II, and processes for their preparation, | 11-25-2010 |
| 20100286219 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders - A method comprising utilizing a compound of formula I: | 11-11-2010 |
| 20100217009 | Process for Preparing Chroman Derivatives - A process for preparing a compound of formula (22), comprising reducing a compound of formula (21), to produce a compound of formula (23), followed by the hydrogenolysis of the compound of formula 23 in a solvent comprising a C | 08-26-2010 |
| 20100137390 | 1,3-Dihydroimidazole-2-Thione Derivatives as Inhibitors of Dopamine-Beta-Hydroxylase - Compounds of formula I and a method for their preparation are described, where R | 06-03-2010 |
| 20100121073 | Process for the Preparation of (R)-5-(2-Aminoethyl)-1-(6,8-Difluorochroman-3-YL)-1,3-Dihydroimidazole-2-- Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-13-2010 |
| 20100113799 | Process for the Preparation of (R) - 5 - (2-Aminoethyl) -1- (6, 8-Difluorochroman-3-YL) -1,3-Dihydroimidazole-2-Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-06-2010 |
| 20100093817 | Compounds - This invention relates to new 6,8-difluorochroman-3-yl-1,3-dihydroimidazole-2-thiones, their preparation, and their use as a medicament. | 04-15-2010 |
| 20100048538 | Therapeutical Uses of Eslicarbazepine - New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases. Preferably the intractable condition is, at least in part, caused by an overexpression of P-gp or MRP. | 02-25-2010 |
| 20100036127 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 02-11-2010 |
| 20090326274 | Sulphonylated Diphenylethylenediamines, Method for Their Preparation and Use in Transfer Hydrogenation Catalysis - A diamine of formula (I) is described in which A is hydrogen or a saturated or unsaturated C1-C20 alkyl group or an aryl group; B is a substituted or unsubstituted C1-C20 alkyl, cycloalkyl, alkaryl, alkaryl or aryl group or an alkylamino group and at least one of X | 12-31-2009 |
| 20090110722 | Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition. | 04-30-2009 |
